… long-term valganciclovir therapy. In the first case, valganciclovir therapy was prolonged beyond
… reduction following valganciclovir administration and no adverse events, CMV viral load …

… CMV Ig G positive pretransplant. Indication for therapy was preemptive treatment of CMV
infection defined as one or two consecutive positive tests of pp65 antigenemia assay or CMV-…

… Several studies have reported the success of IV ganciclovir or oral valganciclovir for
preemptive treatment of CMV infection in liver transplant recipients, including high-risk …

… A CMV strain with a previously unrecognized UL97 mutation N597D was identified in the …
CMV infection with high viral loads accompanying pain and fever while receiving valganciclovir …

… , many centers have adopted valganciclovir as standard prophylaxis for at-risk liver transplant
recipients. At our institution, valganciclovir replaced ganciclovir for CMV prophylaxis in all …

… at high risk for CMV infection (D + /R − ) undergoing preemptive treatment. This study … of
CMV infection in this high-risk face transplant recipient and promoted early acquisition of a CMV-…

… preemptive treatment of CMV infection after LDLT. … Valganciclovir (VGCV), which has an
oral bioavailability of 60%, was recently shown to be effective for the treatment of CMV infection …

… Several studies have reported the success of IV or oral ganciclovir and valganciclovir in
the preemptive treatment of CMV reactivation in liver transplant recipients, including high-risk …

… valacyclovir therapy following maternal CMV infection reduces the risk of congenital CMV
infection and increases the likelihood of infection being … role of prenatal valacyclovir therapy in …

… for CMV prophylaxis in liver transplant recipients, postmarketing studies have shown
valganciclovir … and safety of valganciclovir and ganciclovir for CMV infection prophylaxis in …